enVVeno Medical Corporation (NVNO) Stock

enVVeno Medical Corporation (NVNO) is a Healthcare stock trading at $10.00 (as of 2026-06-18), with a market capitalization of $164865.00 and a trailing P/E of -0.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

enVVeno Medical Corporation is a clinical-stage medical device company developing bioprosthetic tissue-based solutions for treating venous disease. Its products include the VenoValve for surgical replacement of a venous valve and the enVVe system for non-surgical, transcatheter valve replacement, which are intended for clinical use in patients with chronic venous insufficiency.

Valuation — source: SEC EDGAR (first-party)
Price$10.00
Market Cap$164865.00
P/E Ratio-0.3
EV / EBITDA-0.2
Price / Book0.32
DCF Value (model)$-399.76
DCF Upside vs Price-4097.6%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$31243.00
Net Margin-24406.7%
Return on Equity-79.2%
Current Ratio11.89
Valuation vs Sector & Industry
Stock P/E-0.3
Sector P/E (Healthcare)20.9
Industry P/E (Medical Equipment)31.7
vs Sector-101.4%
vs Industry-100.9%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderKINGDON CAPITAL MANAGEMENT, L.L.C. ($366362.00)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEORobert A. Berman
Employees37
CountryUS
IPO Date2018-05-31

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Bone Biologics Corporation (BBLG)
  • ENvue Medical, Inc. (FEED)
  • SeaStar Medical Holding Corporation (ICU)
  • Lifeward Ltd. (LFWD)
  • Amundi Core MSCI Emerging Markets UCITS ETF EUR Dist (AEMD)
  • Bluejay Diagnostics, Inc. (BJDX)
  • Co-Diagnostics, Inc. (CODX)
  • PAVmed Inc. (PAVM)
NVNO earnings history · NVNO institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.